Intra-continental transmission of human invasive Salmonella Typhimurium variants

Chinyere Okoro

Wellcome Trust Sanger Institute Cambridge

01.03.13



3 billion human and animal infections/year





Invasive NTS (iNTS) disease in sub-Saharan Africa, emergence of a new disease?



179 S. Typhimurium genomes sequenced



Sub-Saharan isolates fall into two epidemic lineages that emerged independently





Multiple international transmission events occurred across SSA within each lineage





Successful transmission and clonal expansion is linked to acquisition of MDR genes



Cluster 2



Spread of epidemic invasive S. Typhimurium clones temporally coincides with the HIV epidemic





Okoro et al, Nature Genetics, 2012

Genome degradation – Convergent evolution in human adapted serotypes e.g. S. Typhi



Summaries

- 2 lineages responsible for invasive S. Typhimurium disease epidemic in SSA
- Independent clonal expansion (beginning from the 1960's)
- Successful transmission within a susceptible host population (MDR on Tn21like elements)
- Clonal replacement 2002-2005 (acquisition chloramphenicol resistance in Lineage II)
- Rapid spread enhanced by the increase in susceptible host population (HIV in adults; malaria in children).
- Possible human-to-human transmission

Kariuki et al, 2006; Fashae et al, 2010. Similar isolates to index cases not found in household animals, veterinary animals, environment etc

genomic signatures of adaptation in invasive S. Typmimurium



Acknowledgements

The Wellcome Trust **Sanger Institute** Gordon Dougan Julian Parkhill **Robert Kingsley** Chris Parry Simon Harris **Thomas Connor Health Protection Agency** Sequencing team

UK John Wain Kenya, KEMRI-Wellcome Flizabeth De Pinna

Centro de Investigação em Saúde da Manhiça (CISM) Pedro Alonso Inacio Mandomando

Sam Kariuki

University of Nebraska Stephen Obaro

University of Liverpool Melita Gordon

NVGH

University of Maryland Center for Vaccine Development Mike Levine

Sharon Tennant

Mahidol-Oxford Tropical Medicine **Research Unit** Chris Parry

Malawi-Liverpool–Wellcome Trust **Clinical Research Program**

Rob Heyderman Chisomo Msefula



Calman MacLennan